Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
610.45
1 334.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Ltd
Net Income (Common)
Suven Pharmaceuticals Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
|
Net Income (Common)
₹3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹44.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹110.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹18B
|
CAGR 3-Years
12%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Income (Common)
₹19.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Suven Pharmaceuticals Ltd
Glance View
Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
See Also
What is Suven Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
3B
INR
Based on the financial report for Mar 31, 2024, Suven Pharmaceuticals Ltd's Net Income (Common) amounts to 3B INR.
What is Suven Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
22%
Over the last year, the Net Income (Common) growth was -27%. The average annual Net Income (Common) growth rates for Suven Pharmaceuticals Ltd have been -6% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
